Literature DB >> 15829379

Evaluation of infections in non-small cell lung cancer patients treated with radiotherapy.

Süreyya Sarihan1, Ilker Ercan, Asli Saran, Sibel Kahraman Cetintas, Halis Akalin, Kayihan Engin.   

Abstract

PURPOSE: We aim to determine infections occurring in patients with non-small cell lung cancer during radiotherapy (RT). METHODS AND MATERIALS: A total of 181 patients had been treated with thoracic radiotherapy between October 1995 and December 1999. Radiotherapy was given using 1.8-3Gray (Gy) fraction daily, five fractions a week for a total dose of 59.4Gy (30-70.2Gy). A complete history was collected retrospectively for each patient. All microbiological examinations were performed according to the routine procedures of the hospital laboratory. Numeric and categoric variables were employed such as sex, age, performance status, histology, stage, chemotherapy, usage of corticosteroids, neutropenia, surgery, hospitalization, associated diseases, smoking during treatment, package per year of cigarette smoking, dose of radiotherapy, and response rates.
RESULTS: Infections developed in 84 patients (46%, 84/181) during thoracic radiotherapy. A 101 episodes of infections developed in these patients. Most patients suffered from sputum production (65%), cough (59%), auscultation findings (31%) and fever (31%). Gram-negative bacteria were the most frequently isolated pathogens in the cultures of specimens (70%, 16/23 samples). Neoadjuvant chemotherapy (OR=4.81; 95% CI, 1.57-9.12; p=0.003) and neutropenia (OR=4.25; 95% CI, 1.44-6.89; p=0.009) were found as risk factors for influencing infection based on logistic regression analyses. Package per year of cigarette smoking was found statistically significantly higher in patients with infections than patients without infections (p=0.001). A slight increase in infections, which was of borderline statistical significance (p=0.07), was observed in patients age over 70. Ciprofloxacin and clarithromycin were the most frequently used agents in treatment. Median survival was 9 months in the patients with infection and 13 months in the 97 patients without infection. Overall survival seemed to be statistically significantly better in patients without infection than patients with infection (p=0.042) calculated using Kaplan-Meier method. Based on Cox regression analyses; overall survival was not correlated to presence of infection but associated with poor performance status (</=80) (OR=2.35; 95% CI, 0.85-8.93; p=0.03), and usage of corticosteroids (OR=2.68; 95% CI, 0.98-6.72; p=0.01). The dose of radiation therapy >5940 cGy (OR=2.06; 95% CI, 0.72-7.18; p=0.007) and the absence of response to treatment (OR=2.45; 95% CI, 0.89-14.23; p<0.001) were also found to be risk factors for survival.
CONCLUSIONS: Infections are important causes of morbidity and mortality in lung cancer patients. The control of infection in these patients may improve the survival. Predisposing factors and treatment management approaches in non-small cell lung cancer should be defined carefully.

Entities:  

Mesh:

Year:  2005        PMID: 15829379     DOI: 10.1016/j.cdp.2004.11.001

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  10 in total

Review 1.  Smoking cessation and lung cancer: oncology nurses can make a difference.

Authors:  Mary E Cooley; Rebecca L Sipples; Meagan Murphy; Linda Sarna
Journal:  Semin Oncol Nurs       Date:  2008-02       Impact factor: 2.315

Review 2.  Smoking cessation: an integral part of lung cancer treatment.

Authors:  Janine K Cataldo; Sarita Dubey; Jodi J Prochaska
Journal:  Oncology       Date:  2010-08-11       Impact factor: 2.935

3.  Gram-negative bacteria facilitate tumor outgrowth and metastasis by promoting lipid synthesis in lung cancer patients.

Authors:  Maosong Ye; Xia Gu; Yang Han; Meiling Jin; Tao Ren
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

Review 4.  Systematic Review of Tobacco Use after Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future Research.

Authors:  Jessica L Burris; Jamie L Studts; Antonio P DeRosa; Jamie S Ostroff
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-08-17       Impact factor: 4.254

5.  Behavioral and psychological predictors of chemotherapy adherence in patients with advanced non-small cell lung cancer.

Authors:  Joseph A Greer; William F Pirl; Elyse R Park; Thomas J Lynch; Jennifer S Temel
Journal:  J Psychosom Res       Date:  2008-09-24       Impact factor: 3.006

Review 6.  Smoking cessation in lung cancer-achievable and effective.

Authors:  Stefan Andreas; Achim Rittmeyer; Marc Hinterthaner; Rudolf M Huber
Journal:  Dtsch Arztebl Int       Date:  2013-10-25       Impact factor: 5.594

7.  Worse lung cancer outcome in patients with lower respiratory tract infection confirmed at time of diagnosis.

Authors:  Attila Nagy; Veronika Müller; Abigel M Kolonics-Farkas; Noemi Eszes; Krisztina Vincze; Gabor Horvath
Journal:  Thorac Cancer       Date:  2019-07-17       Impact factor: 3.500

8.  Expression of miRNA-601 and PD-L1 among Iranian Patients with Lung Cancer and Their Relationship with Smoking and Mycoplasma Infection.

Authors:  Mahla Ganjali; Babak Kheirkhah; Kumarss Amini
Journal:  Cell J       Date:  2021-12-29       Impact factor: 2.479

Review 9.  Impact of Tobacco Smoking on Outcomes of Radiotherapy: A Narrative Review.

Authors:  Adrian Perdyan; Jacek Jassem
Journal:  Curr Oncol       Date:  2022-03-24       Impact factor: 3.109

10.  A novel use for routine CBCT imaging during radiotherapy to detect COVID-19.

Authors:  A Clough; J Sanders; K Banfill; C Faivre-Finn; G Price; C L Eccles; M C Aznar; M Van Herk
Journal:  Radiography (Lond)       Date:  2021-07-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.